Survival of patients with stage IA malignant melanoma

Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study

BACKGROUND AND OBJECTIVES

Depth of invasion and stage of the disease are established prognostic indicators in cutaneous malignant melanoma. The role of other parameters is still an open problem.

METHODS

In 93 consecutive patients with cutaneous malignant melanoma, the level of invasion, tumor thickness, ulceration, vascular invasion, lymphoplasmocytic infiltrates, and mitotic index were evaluated by histology. Expression of Ki-67 and PCNA proliferative antigens together with vimentin, S100, and HMB 45 proteins were assessed by immunohistochemistry.

RESULTS AND CONCLUSIONS

Disease-free and overall survival were correlated with tumor stage, tumor thickness, level of invasion, macroscopic pattern, ulceration, vascular invasion, expression of HMB 45, PCNA, and Ki-67/MIB1. Stage, HMB 45, and PCNA were independent prognostic factors for disease-free survival, whereas tumor stage, tumor thickness, and expression of both proliferative antigens influenced overall survival independently. The variables studied demonstrated reciprocal correlation; therefore, analysis of many prognostic parameters in malignant melanoma could be recommended.

Therapeutic node dissections in malignant melanoma

BACKGROUND

Therapeutic lymphadenectomies involve the dissection and removal of clinically enlarged, histologically positive nodes at the regional nodal basin, in the absence of detectable distant disease.

METHODS

The literature dealing with therapeutic lymphadenectomies in malignant melanoma was reviewed.

RESULTS

The rate of wound complications varies with the particular nodal basin. The 5-year survival varies from 19% to 38%, with an average of 26%. Survival is affected primarily by the number of histologically positive nodes and extracapsular spread, and secondarily by the extent of disease at the various levels of the nodal basin, fixation of the nodes, and, probably, the preceding disease-free interval. Prognostic parameters of the primary lesion, e.g., thickness, ulceration, and location, also may have an effect on survival. The rate of local recurrence at the nodal basin after lymphadenectomy has varied from 0.8% to 52%. Adjuvant therapy with interferon alfa-2b has improved the 5-year disease-free survival from 26% to 37%.

CONCLUSIONS

Therapeutic node dissections in melanoma provide an appreciable 5-year survival rate, which is further augmented by adjuvant therapy. Many series report a significant rate of local recurrence at the nodal basin following therapeutic dissection. Complete lymphadenectomy reduces the rate of local failure with its attendant morbidity.

Surgical treatment of malignant melanoma

The surgical treatment of the primary melanoma site has been made more rational through correlations of rates of local control with various margins of resection in the context of the dominant prognostic indicator for localized melanoma, the thickness of the primary lesion. It is now known that for lesions less than 1 mm in thickness, a 1-cm margin is satisfactory. For lesions 1 to 4 mm thick, a 2-cm margin is adequate according to the results of a multi-institutional, randomized, surgical trial. Lesions thicker than 4 mm should be treated with a margin larger than 2 cm where the anatomy permits, although the main concern for these lesions is their high propensity for distant dissemination. Elective dissection has not been shown to alter survival significantly in prospective randomized trials. Surgical treatment of distant metastases is indicated for the palliation of a symptomatic lesion, for example, solitary brain metastasis or gastrointestinal metastases.